Metro Drugs 3rd Avenue Corp, New York, NY

Is Metro Drugs 3rd Avenue Corp registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.

Does Metro Drugs 3rd Avenue Corp hold a New York pharmacy license?

State pharmacy license records for New York are not checked: the Office of the Professions’ online verification search requires an access key and a check that the user is a person, and its bulk verification files are released only on request. This index reads only that state’s board actions.

Has Metro Drugs 3rd Avenue Corp had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 untitled letter (Jan 8, 2021), 1 state referral letter (Sep 22, 2021) and 1 FMD-145 letter (Sep 22, 2021) for Metro Drugs 3rd Avenue Corp. State board actions: no New York State Education Department action under this exact name and city was found in the New York State Education Department’s list of Board of Regents disciplinary actions against pharmacy establishments (actions dated Jan 14, 1994 to May 19, 2026) on Nov 8, 2026. The state referral and handoff letters above are FDA’s letters to the state, not board actions.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Metro Drugs 3rd Avenue Corp
Location
New York, NY
Type as FDA labels it
503A
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
1
Warning letters on FDA’s actions page
0
Latest action on that page
Sep 22, 2021
FDA Data Dashboard inspections
1 inspection: 1 VAI; 1 published Form 483
Form 483 text on this page
1 Form 483, 4 observations
State board records
Not checked (license records); board actions matched: 0

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Metro Drugs 3rd Avenue Corp, a 503A facility, with 4 dated actions.

Document
Sep 22, 2021State referral letterState Referral Letter Issued 09/22/2021Not linked by FDA
Sep 22, 2021FMD-145 letterFMD-145 Letter Issued 09/22/2021Not linked by FDA
Jan 8, 2021Untitled letterUntitled Letter Issued 01/08/2021FDA copy (archived)
Apr 5, 2019Form 483483 Issued 04/05/2019FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Metro Drugs 3rd Avenue Corp, New York, NY (FEI number 3011795133), matched to this page by exact name, city and state. It lists 1 inspection: 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Apr 5, 2019Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30117951331085232

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483 for this site has 4 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Mar 14, 2019 to Apr 5, 2019: 4 observations

Firm on the cover
, New Yo rk, NY 10065-5771
FEI number
3011795133
Establishment type on the cover
Producer of Steril e and Non-Sterile Drug Products 1bis document lists observations made by the FDA representative( ) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency detennination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement corrective action in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this infonrmation to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above.
FDA district office on the cover
158-15 Liberty Avenue Jamaica, NY 11433
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Disinfecting agents and cleaning pads or wipes used in the ISO 5 area aseptic processing areas are not sterile.

Specifically on 3/14/ 19, I observed an aseptic operator using non-sterile <Redacted B4> Wipes <Redacted B4>, to disinfect the ISO 5 <Redacted B4> !laminar flow hood and as a place mat where syringes, needles, and sterile <Redacted B4> were placed upon during aseptic filling.

Observation 2

Your finn released drug product in which the strength differs from, or its purity or quality falls below, that which it purpmts or is represented to possess.

Specifically, the following out-of-specification potency results were observed:

• T3 6mcg capsules S/R, lot #01082019@9, Liothyronine Sodium (T3) potency: 86.3%;

• T3 20mcg capsules SIR, lot #01252019@7, Liothyronine Sodium (T3) potency: 116%;

• T3 30mcg lot #01252019@14, Liothyronine Sodium (T3) potency: 75.0%;

• Estriol/ DHEA/ Testosterone/ Pregnenolone 100mg/4mg/45mg/mg/mL, lot #02 1420 19@1, DHEA potency: 81.3%, Estriol potency: 77 .2%, and Testosterone potency: 84.5%;

• Methylcobalamin lO00mcg/mL (PF) injectable, lot #02212019@1, Methylcobalamin potency: 53.3%;

No product impact assessment has been conducted and recorded, except for the Tri-Mix Quad and Atropine 0.1% Stock Solution.

Observation 3

Media fills were not performed that closely simulate aseptic production operations incorporating as appropriate, worst-case activities and conditions that provide a challenge to aseptic operations.

Specifically,

a) Your fnm did not evaluate any conditions that provide a challenge to aseptic operations as part of the firm's media fill. For example operators do leave and reenter the ISO 5 ai·ea during production; however, this was not addressed in any of the media fills.

b) One of your phaimacy technicians was not qualified by a media fill prior to prepaiing sterile drug products and continued to perfo1m aseptic processing of sterile mug products despite failing a media fill perfo1med on 1/17/19.

Observation 4

ISO-5 classified areas were not certified under dynamic conditions.

Specifically, unidirectional airflow was not verified under dynamic conditions. The most recent smoke pattern tests were perfonned on <Redacted B4> on the fnm's ISO 5 biological safety cabinet and ISO 5 laminai· flow clean bench under static conditions.

Specifically, pressure differential readings <Redacted B4> j, which monitors the pressure from the ISO 7 Hazardous Prep Room to the ISO 8 Non-Hazardous Prep/Buffer Room (established negative pressure differential limi <Redated B4> were out of specification on 1/14/19 to 1/15/19 all of December 2018, and 11/1/18 to 11/27 /18. Mixing of non-sterile active pharmaceutical ingredients and non-sterile commercial products is conducted in the <Redacted B4> hoods <Redaceted B4> located in both the ISO 7 Hazardous Prep Room and the ISO 8 Non-Hazardous Prep/Buffer Room. No product impact assessment was conducted and recorded.

State board of pharmacy records

State pharmacy license records for New York are not checked: the Office of the Professions’ online verification search requires an access key and a check that the user is a person, and its bulk verification files are released only on request. This index reads only that state’s board actions. Board actions source.

What this covers: Board of Regents disciplinary actions against pharmacy establishments from the Office of the Professions’ summaries for the pharmacy profession, which start in 1994 (105 of 105 list pages read). These are final Regents actions, mostly consent orders; open complaints and charges not yet decided are not listed. Actions against individual pharmacists are not copied. New York pharmacy licenses and registrations are not checked. Actions in the data are dated Jan 14, 1994 to May 19, 2026.

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.